Zobrazeno 1 - 10
of 52
pro vyhledávání: ''
Publikováno v:
Cellular Oncology (2211-3428). Feb2016, Vol. 39 Issue 1, p89-95. 7p.
Publikováno v:
Cellular Oncology (2211-3428). Apr2011, Vol. 34 Issue 2, p71-88. 18p.
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Autor:
Anupam Batra, C. Michael DiPersio, Anshu Aggarwal, David M. Jones, Rami N. Al-Rohil, Paul J. Feustel
Publikováno v:
BMC Cancer
Background Expression of integrin α3β1 is associated with tumor progression, metastasis, and poor prognosis in several cancers, including breast cancer. Moreover, preclinical studies have revealed important pro-tumorigenic and pro-metastatic functi
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Publikováno v:
BMC Cancer
Background Although mammary microcalcification is frequently observed and has been associated with poor survival in patients with breast cancer, the genesis of calcification remains unclear. Carbonic anhydrase I (CA1) has been shown to promote calcif
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou
Autor:
Sandra Salvi, Pier Vitale Nuzzo, L. Zinoli, Francesco Boccardo, Simona Boccardo, Alessandra Rubagotti
Publikováno v:
BMC Cancer
Background PN is a secreted cell adhesion protein critical for carcinogenesis. In breast cancer, it is overexpressed compared to normal breast, and a few reports suggest that it has a potential role as a prognostic marker. Methods Tumour samples obta
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 228 (2010)
BMC Cancer
BMC Cancer
Background The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recogni